These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 33486860)

  • 1. Trichobiolight: A new, effective protocol in the treatment of androgenetic alopecia and telogen effluvium.
    Piccolo D; Crisman G; Conforti C; Buzzi M; Genovesi C; Marchi D; Mazzaracchio D; Goldust M
    Dermatol Ther; 2021 Mar; 34(2):e14799. PubMed ID: 33486860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Red LED light therapy for telogen effluvium in the course of long COVID in patients with and without androgenetic alopecia.
    Gerkowicz A; Bartosińska J; Krakowski P; Karpiński R; Krasowska D; Raczkiewicz D; Kwasny M; Krasowska D
    Ann Agric Environ Med; 2024 Jun; 31(2):239-247. PubMed ID: 38940108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonscarring scalp alopecia: Which laboratory analysis should we perform on whom?
    Öner Ü; Akdeniz N
    Turk J Med Sci; 2022 Feb; 52(1):188-194. PubMed ID: 34688244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary results of the use of scalp microneedling in different types of alopecia.
    Starace M; Alessandrini A; Brandi N; Piraccini BM
    J Cosmet Dermatol; 2020 Mar; 19(3):646-650. PubMed ID: 31254437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trichotillomania: Bizzare Patern of Hair Loss at 11-Year-old Girl.
    Zímová J; Zímová P
    Acta Dermatovenerol Croat; 2016 Jun; 24(2):150-3. PubMed ID: 27477178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with telogen effluvium and mild androgenetic alopecia.
    Cedirian S; Bruni F; Quadrelli F; Caro G; Fortuna M; Rossi A; Piraccini BM; Starace M
    J Cosmet Dermatol; 2023 Dec; 22(12):3347-3351. PubMed ID: 37415302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follicular density and ratios in scarring and nonscarring alopecia.
    Horenstein MG; Bacheler CJ
    Am J Dermatopathol; 2013 Dec; 35(8):818-26. PubMed ID: 23435361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients with profuse hair shedding may reveal anagen hair dystrophy: a diagnostic clue of alopecia areata incognita.
    Quercetani R; Rebora AE; Fedi MC; Carelli G; Mei S; Chelli A; Poli E
    J Eur Acad Dermatol Venereol; 2011 Jul; 25(7):808-10. PubMed ID: 20946585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation and diagnosis of the hair loss patient: part I. History and clinical examination.
    Mubki T; Rudnicka L; Olszewska M; Shapiro J
    J Am Acad Dermatol; 2014 Sep; 71(3):415.e1-415.e15. PubMed ID: 25128118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral minoxidil use in androgenetic alopecia and telogen effluvium.
    Feaster B; Onamusi T; Cooley JE; McMichael AJ
    Arch Dermatol Res; 2023 Mar; 315(2):201-205. PubMed ID: 35244759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent modalities in treatment of telogen effluvium: Comparative study.
    Khattab FM; Rady A; Khashaba SA
    Dermatol Ther; 2022 Oct; 35(10):e15720. PubMed ID: 35851518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of an oral supplement containing amino acids, iron, selenium, and marine hydrolyzed collagen in subjects with hair loss (androgenetic alopecia, AGA or FAGA or telogen effluvium). A prospective, randomized, 3-month, controlled, assessor-blinded study.
    Milani M; Colombo F;
    Skin Res Technol; 2023 Jun; 29(6):e13381. PubMed ID: 37357646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HrQoL in hair loss-affected patients with alopecia areata, androgenetic alopecia and telogen effluvium: the role of personality traits and psychosocial anxiety.
    Russo PM; Fino E; Mancini C; Mazzetti M; Starace M; Piraccini BM
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):608-611. PubMed ID: 30394586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of ALRV5XR in women with androgenetic alopecia or telogen effluvium: A randomised, double-blinded, placebo-controlled clinical trial.
    Feldman PR; Fiebig KM; Piwko C; Mints BM; Brown D; Cahan DJ; Guevara-Aguirre J
    EClinicalMedicine; 2021 Jul; 37():100978. PubMed ID: 34235415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosing and treating hair loss.
    Mounsey AL; Reed SW
    Am Fam Physician; 2009 Aug; 80(4):356-62. PubMed ID: 19678603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diseases on hair follicles leading to hair loss part I: nonscarring alopecias.
    Wiedemeyeer K; Schill WB; LOser C
    Skinmed; 2004; 3(4):209-14. PubMed ID: 15249781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and histological challenge in the differential diagnosis of diffuse alopecia: female androgenetic alopecia, telogen effluvium and alopecia areata--part II.
    Werner B; Mulinari-Brenner F
    An Bras Dermatol; 2012; 87(6):884-90. PubMed ID: 23197208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral supplementation in female telogen effluvium: a clinical and instrumental objective evidence of efficacy and tolerability of new oral cosmetic treatment.
    Starace M; Carpanese MA; Alessandrini A; Bruni F; Piraccini BM
    Ital J Dermatol Venerol; 2023 Feb; 158(1):55-59. PubMed ID: 36645365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and histological challenge in the differential diagnosis of diffuse alopecia: female androgenetic alopecia, telogen effluvium and alopecia areata - part I.
    Werner B; Mulinari-Brenner F
    An Bras Dermatol; 2012; 87(5):742-7. PubMed ID: 23044568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and management of the hair loss patient.
    Stroud JD
    Cutis; 1987 Sep; 40(3):272-6. PubMed ID: 3652735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.